A new study has concluded that added risk for Alzheimer’s disease and dementia among Medicare patients with prostate cancer who were treated with androgen deprivation therapy (ADT) was minimal in men treated between 2001 and 2014. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, Alzheimer's, androgen, dementia, deprivation | 1 Comment »
A few days ago we commented briefly on a paper by Haque et al. on the risk for cardiovascular complications and side effects of ADT in men initially diagnosed with localized prostate cancer and supposedly managed, initially, on active surveillance. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, cardiovascular, deprivation, side effect | 1 Comment »
Not so long ago, we addressed the question of whether first-line androgen deprivation therapy (ADT) was really an appropriate form of care for any man with localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, arrhythmia, cardiovascular, deprivation, failure, heart, risk | 9 Comments »
Some 15 months ago, we reported the initial, primary results of the TOAD trial, which showed an overall survival benefit for immediate as opposed to delayed initiation of androgen deprivation therapy (ADT) in non-metastatic patients considered to be inappropriate for curative therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, delayed, deprivation, immediate, quality of life, survival, TOAD | 6 Comments »
One really has to wonder whether we are still treating elderly men, initially diagnosed with organ-confined prostate cancer, with first-line or “primary” androgen deprivation therapy ADT)! And if we are, why on Earth is that? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: ADT, androgen, appropriate, deprivation, elderly, organ-confined, primary | 4 Comments »
